Table 2.
HER2‐positive rates for tumours from UK patients and those from the whole patient population, using the recording centre's categorical assignment to define HER2 status
| UK | P value | All | P value | |
|---|---|---|---|---|
| All cases, n (%) | 19 210 (13.3) | na | 24 614 (13.1) | na |
| Age at test | ||||
| <56 years | 5932 (16.4) | <0.0001 | 8002 (16.1) | <0.0001 |
| ≥56 years | 7445 (11.6) | 10 091 (11.4) | ||
| Referral pathway | ||||
| Screen detected | 205 (8.7) | <0.0001 | 418 (9.0) | <0.0001 |
| Symptomatic | 520 (13.7) | 1119 (13.3) | ||
| Tissue type (sample type) | ||||
| Axilla/nodes | 838 (14.9) | <0.05* | 1006 (15.7) | <0.0001* |
| Primary tumour – core biopsy | 9017 (13.2) | <0.05† | 12 516 (13.0) | <0.0001† |
| Primary tumour – excision | 3386 (13.6) | ns‡ | 4330 (13.1) | ns‡ |
| Metastatic disease by site | ||||
| Bone | 20 (9.0) | <0.05§ | 41 (9.2) | <0.05§ |
| Cutaneous | 162 (15.1) | ns¶ | 222 (15.0) | <0.05¶ |
| Visceral | 171 (14.6) | ns** | 304 (15.3) | ns** |
| Histological type | ||||
| Carcinoma in situ | 133 (5.7) | See legend notes†† | 302 (8.0) | See legend notes†† |
| IDC/NOS | 7887 (15.2) | 10 134 (15.3) | ||
| ILC | 446 (5.6) | 573 (5.5) | ||
| Mixed IDC/ILC | 105 (8.5) | 115 (7.9) | ||
| Special type | 68 (5.1) | 87 (5.3) | ||
| Tumour grade | ||||
| Grade 1 | 268 (2.5) | <0.0001‡‡ | 332 (2.5) | <0.0001‡‡ |
| Grade 2 | 3723 (10.6) | 4716 (10.8) | ||
| Grade 3 | 4915 (24.2) | 5821 (23.8) | ||
| Tumour size category (diameter) | ||||
| <20 mm | 922 (12.1) | <0.0001‡‡ | 1188 (11.8) | <0.0001‡‡ |
| 20 to <50 mm | 831 (15.1) | 1053 (13.9) | ||
| ≥50 mm | 203 (16.5) | 274 (14.6) | ||
| Nodal status | ||||
| N0 | 787 (11.4) | <0.0001‡‡ | 1006 (11.0) | <0.0001‡‡ |
| N1 | 388 (14.4) | 482 (13.3) | ||
| N2 | 141 (17.1) | 172 (16.3) | ||
| N3 | 163 (25.1) | 184 (21.8) | ||
| ER status | ||||
| Negative | 3182 (25.3) | <0.0001 | 4183 (25.5) | <0.0001 |
| Positive | 6320 (10.5) | 8317 (10.6) | ||
| PR status | ||||
| Negative | 4106 (22.7) | <0.0001 | 5566 (23.4) | <0.0001 |
| Positive | 2916 (8.5) | 3836 (8.7) | ||
| Combined ER and PR status | ||||
| ER‐negative/PR‐negative | 2492 (25.4) | ns | 3388 (26.1) | ns |
| ER‐negative/PR‐positive | 161 (25.2) | 197 (25.9) | ||
| ER‐positive/PR‐negative | 1604 (19.5) | <0.0001 | 2155 (20.1) | <0.0001 |
| ER‐positive/PR‐positive | 2750 (8.1) | 3633 (8.4) | ||
ER‐negative: Centre assigned, or Allred <3, or % positive <1%, or H‐score <1.
ER‐positive: Centre assigned, or Allred ≥3, or % positive ≥1%, or H‐score ≥1.
PR‐negative: Centre assigned, or Allred <4, or % positive <10%, or H‐score <10.
PR‐positive: Centre assigned, or Allred ≥4, or % positive ≥10%, or H‐score ≥10.
Refer to Table 1 for data on the total number of cases in each category.
na = not applicable, ns = not significant at p < 0.05.
Axilla/nodes versus primary tumour – core biopsy.
Axilla/nodes versus primary tumour – excision.
Primary tumour – core biopsy versus primary tumour – excision.
Bone versus cutaneous.
Bone versus visceral.
Cutaneous versus visceral.
Rate for IDC/NOS was significantly different from all other groups (p < 0.001), which were not significantly different from each other at p < 0.05.
Test for trend.